tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lepu Biopharma Reports First-Ever Profit Amid Revenue Surge

Story Highlights
  • Lepu Biopharma expects a profit of not less than RMB24 million for the first half of 2025.
  • Revenue growth from PUYOUHENG sales and a licensing deal with ArriVent BioPharma drove the profit turnaround.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Lepu Biopharma Reports First-Ever Profit Amid Revenue Surge

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an announcement.

Lepu Biopharma Co., Ltd. announced a positive profit alert, expecting a profit of not less than RMB24 million for the first half of 2025, marking a significant turnaround from a loss of approximately RMB197.0 million in the same period of 2024. This improvement is attributed to substantial revenue growth driven by increased sales of PUYOUHENG and income from a licensing collaboration with ArriVent BioPharma, Inc. The announcement indicates a strong operational performance and potential positive implications for stakeholders, although the results are preliminary and subject to finalization.

More about Lepu Biopharma Co. Ltd. Class H

Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, with notable products including PUYOUHENG (Pucotenlimab Injection) and a licensing collaboration for MRG007 with ArriVent BioPharma, Inc.

Average Trading Volume: 29,539,096

Technical Sentiment Signal: Buy

Current Market Cap: HK$14.78B

For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1